

Ocata Therapeutics

Pharma & biotech
17 April 2015

An eye on commercialisation

Ocata has completed enrolment and published encouraging results in its Phase I/II trial of stem cell therapy in both dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD). It is pursuing the quicker orphan drug approval process of SMD and the large potential market of AMD by beginning an AMD Phase II trial and a pivotal trial in SMD. It has also secured a licensing agreement to use induced pluripotent stem cells (iPSC) as a platform for differentiating ocular tissue for other diseases. In spite of this recent clinical momentum, a weak capital position will require additional funding to reach clinical approval.

Encouraging Phase I/II trial builds momentum

Ocata dosed the final patient and reported interim follow-up of initial patients in its Phase I/II trial with retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESC). This data shows that the hESC grafts appeared to be safe and possibly viable 22 months after treatment. Of the 18 patients treated, 10 had improved vision. These results have led to Advanced Therapy Medicinal Product (ATMP) designation providing momentum.

Two paths forward to market entry

Ocata is targeting both the 27 million patient dry AMD market and the orphan disease market of SMD. Currently there are no approved treatments for either disorder; however, there is intense competition in this segment. There are plans to follow the current trial with Phase II trials for AMD and a pivotal trial for SMD. With the ATMP designation and the SMD pivotal trial status, positive results may lead to regulatory approval.

Recent deal enhances stem cell platform

As Ocata matures its pipeline, it has announced a licensing agreement to use iPSCs in addition to hESCs. iPSCs will complement the current pipeline and expand the platform as it explores differentiating and implanting other tissues in the eye. So far the iPSCs have scant data, but company releases are encouraging.

Valuation: Weak capitalisation dampens momentum

Ocata ended FY14 with \$4m in cash and a burn rate of \$35.29m, causing concern regarding capital structure and the potential need for further debt or equity financing. With a discount reflecting these concerns, the EV of \$241m only partially captures the potential of its stem cell therapies in dry AMD and SMD markets.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	0.2	(31.0)	(1.34)	0.0	N/A	N/A
12/14	0.2	(34.7)	(1.17)	0.0	N/A	N/A
12/15e	10.2	(9.8)	(0.26)	0.0	N/A	N/A

Source: Bloomberg

Price **\$7.00**
Market cap **\$245m**

Share price graph



Share details

Code OCAT
 Listing NASDAQ
 Shares in issue 35.04m

Business description

Ocata Therapeutics is a clinical-stage biotechnology company specialising in regenerative ophthalmology using stem cells. It is currently in Phase I trials for dry macular degeneration, Stargardt's disease and myopic macular degeneration. They are in preclinical studies outside ophthalmology.

Bull

- Potential market of 27 million patients for dry AMD.
- Phase I/II trials encouraging with Advanced Therapy Medicinal Product designation granted.
- iPSC licensing agreement expands technology platform to other ocular tissues.

Bear

- Only just beginning Phase II trials.
- Weak capitalisation structure.
- Intense competition in dry AMD market.

Analysts

George Magrath, MD MBA +1 646 653 7030
 Dr Mick Cooper +44 (0)20 3077 5734
healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2015]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent. The research analyst primarily responsible for the preparation of this report personally holds an equity position in the company of less than 1%.